Gynakol Geburtshilfliche Rundsch. 1994;34(3):186-8. doi: 10.1159/000272367.
The effectiveness of a zidovudine prophylaxis to decrease vertical HIV transmission was tested in a multi-centre (59 clinics in the USA and France), randomised, placebo-controlled study. The mother was given zidovudine orally from the 14th gestational week and intravenously during delivery. The child was treated orally for the first 6 weeks of life. This prophylactic treatment resulted in a significant reduction of vertical HIV transmission from 26 to 8%. Although there are still some open questions, especially concerning the long-term consequences for the child, the Swiss Associations of Gynaecology and Obstetrics and of Paediatrics recommend using zidovudine for prophylaxis in the routine care of HIV-infected pregnant women.
在一项多中心（美国和法国的59家诊所）随机、安慰剂对照研究中，对齐多夫定预防降低HIV垂直传播的有效性进行了测试。母亲从妊娠第14周开始口服齐多夫定，并在分娩时静脉注射。孩子在出生后的前6周接受口服治疗。这种预防性治疗使HIV垂直传播率从26%显著降低至8%。尽管仍有一些未解决的问题，特别是关于对孩子的长期影响，但瑞士妇产科协会和儿科学会建议在对感染HIV的孕妇进行常规护理时使用齐多夫定进行预防。
